Bristlecone Value Partners’s AstraZeneca AZN Stock Holding History

Bristlecone Value Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.75M	Buy	+17,014	New	+$2.84M	2.14%	14

Other funds holding AZN

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $162B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Bristlecone Value Partners's AZN Position: Q3 2026 in Review

Bristlecone Value Partners opened a new position in AstraZeneca (AZN) in Q3 2026: 17,014 shares worth $2.75M. The stake represents 2.14% of the portfolio and ranks #14 among its holdings.

1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Bristlecone Value Partners held 17,014 shares of AstraZeneca worth $2.75M as of Q3 2026.
AstraZeneca was a new Bristlecone Value Partners position in Q3 2026.
AstraZeneca made up 2.14% of Bristlecone Value Partners's portfolio in Q3 2026, its #14 holding.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Bristlecone Value Partners's 13F filing for Q3 2026, filed 12 Nov 2026.